8-K: McKesson Reports Strong Fiscal 2024 Results, Provides Upbeat 2025 Outlook

McKesson Corporation announced its fourth quarter and full-year fiscal 2024 results, highlighting revenue growth and providing a positive outlook for fiscal year 2025.

Summary

• McKesson's consolidated revenues for the fourth quarter of fiscal year 2024 reached $76.4 billion, an 11% increase year-over-year.
• Full-year consolidated revenues totaled $309.0 billion, a 12% increase compared to the previous year.
• Earnings per diluted share from continuing operations for the fourth quarter were $6.02, up from $5.71, while full-year earnings per diluted share were $22.39, down from $25.05.
• Adjusted earnings per diluted share for the fourth quarter were $6.18, a decrease of 14%, and full-year adjusted earnings per diluted share were $27.44, a 6% increase.
• The company generated $4.3 billion in cash flow from operations and $3.6 billion in free cash flow for the full year.
• McKesson returned $3.3 billion of cash to shareholders through $3.0 billion in stock repurchases and $314 million in dividend payments.
• The company's fiscal 2025 adjusted earnings per diluted share guidance is between $31.25 and $32.05, indicating a projected growth of 14% to 17%.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, positive future guidance, and significant cash flow. However, there are some concerns about the decrease in adjusted EPS in the fourth quarter and the challenges in the Medical-Surgical and International segments.

Positives

• McKesson experienced strong revenue growth in both the fourth quarter and full year, driven by the U.S. Pharmaceutical segment.
• The company's adjusted earnings per diluted share for the full year increased by 6%.
• McKesson generated significant cash flow from operations and free cash flow.
• The company is projecting a substantial increase in adjusted earnings per diluted share for fiscal year 2025.
• McKesson's CoverMyMeds business has made a significant positive impact on medication affordability and access for patients.
• The company has been recognized for innovation and workplace excellence.

Negatives

• Adjusted earnings per diluted share for the fourth quarter decreased by 14% due to a higher tax rate.
• Full-year earnings per diluted share from continuing operations decreased by $2.66.
• The Medical-Surgical Solutions segment saw a 12% decrease in adjusted operating profit for the full year.
• The International segment experienced a 24% decrease in adjusted operating profit for the full year due to divestitures.

Risks

• McKesson is subject to legal disputes and settlements, including those related to opioid distribution.
• The company faces risks related to changing healthcare laws and regulations.
• Cybersecurity incidents and data breaches pose a threat to the company's operations.
• Changes in customer contracts and payment defaults could impact financial performance.
• The company is exposed to risks related to product supply disruptions and changes in economic conditions.
• McKesson is subject to risks related to global climate change and related legal and regulatory responses.

Future Outlook

McKesson anticipates fiscal 2025 adjusted earnings per diluted share to be between $31.25 and $32.05, reflecting continued operating momentum and a strong financial position.

Management Comments

• McKesson reported fourth quarter results, marking the close to a strong fiscal 2024, underpinned by continued momentum across the enterprise, said Brian Tyler, chief executive officer.
• Looking ahead to fiscal 2025, we are well-positioned to further expand on the extensive range of our assets and capabilities, execute against our strategic initiatives, foster sustainable growth, and create long-term value for all stakeholders, said Mr. Tyler.

Industry Context

McKesson's results reflect the ongoing trends in the healthcare industry, including increased demand for specialty pharmaceuticals and technology solutions. The company's focus on oncology and biopharma services aligns with the growing importance of these areas in healthcare.

Comparison to Industry Standards

• McKesson's revenue growth of 12% for the full year is strong compared to some of its peers in the pharmaceutical distribution industry, such as Cardinal Health and AmerisourceBergen, which have seen more modest growth.
• The company's adjusted EPS growth of 6% for the full year is solid, but the 14% decrease in adjusted EPS for the fourth quarter is a concern, and will need to be addressed in future quarters.
• McKesson's free cash flow of $3.6 billion is a positive sign of its financial health and ability to invest in future growth.
• The company's guidance for 14-17% adjusted EPS growth in fiscal 2025 is ambitious and suggests confidence in its future performance.

Legal Proceedings

• McKesson is involved in litigation related to opioid distribution, which could result in significant charges.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and cash returns.
• Employees are recognized for their contributions to the company's success.
• Customers and partners will benefit from McKesson's continued investment in its services and platforms.
• Patients will benefit from improved access to and affordability of medications through McKesson's initiatives.

Next Steps

• McKesson will hold a conference call on May 7, 2024, to discuss the financial results.
• McKesson management will participate in the BofA Securities 2024 Healthcare Conference on May 16, 2024.

Key Dates

Keywords

McKesson, pharmaceutical distribution, healthcare services, financial results, earnings, revenue, adjusted EPS, cash flow, oncology, biopharma, prescription technology, medical-surgical solutions